Risultati della ricerca - Azar Shahraz
- Mostra 1 - 3 risultati su 3
-
1
Reply to “High Pharmacokinetic Variability and Unrecognized Limitations in First‐Line Osimertinib Plus Chemotherapy for EGFR ‐Mutated NSCLC ” Autoría: Azar Shahraz, Jincheng Yang, Diansong Zhou, Karthick Vishwanathan, Dana Ghiorghiu, Yuri Rukazenkov, Aarti Sawant‐Basak
Pubblicazione 2025Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
2
Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR ‐Mutated Advanced NSCLC Autoría: Jincheng Yang, Damilola Olabode, Aarti Sawant‐Basak, Richard Baldry, Karthick Vishwanathan, Srinivas Bachina, Alexandar Todd, Dana Ghiorghiu, Yuri Rukazenkov, Diansong Zhou, Azar Shahraz
Pubblicazione 2025Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
3
A mechanistic PK/PD model of AZD0171 (anti‐LIF) to support Phase II dose selection Autoría: Azar Shahraz, Mark Penney, Juliana Candido, Grace Opoku‐Ansah, Melanie Neubauer, Jim Eyles, Oluwaseun Ojo, Nelson Liu, Nadia M. Luheshi, Alex Phipps, Karthick Vishwanathan
Pubblicazione 2024Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso